Sysmex America, Inc., the United States subsidiary for Sysmex Corporation, Kobe, Japan, announced that the company’s President and Chief Executive Officer, John Kershaw, has been appointed an Executive Officer of Sysmex Corporation. Kershaw’s appointment marks the first time an executive from an overseas subsidiary has been appointed. As an Executive Officer, Kershaw will serve in a consultative capacity to the corporation’s president and governing board while maintaining his leadership position with Sysmex America.
Sysmex America has oversight of the company’s subsidiaries in Canada, Latin America and the Caribbean. Sysmex is a global leader in medical diagnostic testing equipment and information systems technology and services hospitals and healthcare networks, reference laboratories and physicians offices worldwide.
During Kershaw’s leadership, the U.S. subsidiary has achieved major milestones including significant North American market share growth and international expansion to the Latin American and Caribbean markets. Additionally, the company has introduced industry-changing products in those markets such as the Sysmex® XN-Series Automated Hematology Analyzers and Sysmex WAM™ Middleware. The company has also been recognized by national entities for its outstanding workplace practices and active community involvement and has opened a Research & Development Center to help accelerate the globalization of the Corporation’s R & D structure with the goal of realizing personalized medicine.
Kershaw’s 23-year career with Sysmex Corporation, Kobe, Japan, began as a result of the company’s acquisition of L.E.P. Scientific in 1991. His experience as the Manager of Sales and Marketing in the newly formed subsidiary eventually led him to serve as the Marketing Director for Sysmex’s corporate European headquarters in Hamburg, Germany.
Three years after relocating to Hamburg, Kershaw was promoted to Vice President of Sysmex Europe where he directed the efforts of all of Sysmex’s European business operations. A market growth rate of 18% in a two-year period under his leadership resulted in Kershaw’s promotion yet again to Executive Vice President and Board Member for Sysmex Europe. At that time, he was also appointed to serve as a board member of Sysmex’s software company located in Belgium, Sysmex MOLIS.
As a result of Sysmex’s strategic move to establish a new software products business in the United Statesand the requirement to lead an aggressive growth campaign in the Laboratory Diagnostics division of the company, Kershaw was transferred to America where he became Chief Operating Officer, Managing Director, and a Board Member of Sysmex’s U.S. headquarters, Sysmex Corporation of America, now known as Sysmex America, Inc.
Kershaw’s education lies in the areas of hematology, microbiology, biochemistry, immunology, anatomic pathology and blood transfusion. He is a fellow of the Association of Medical Technologists in the United Kingdom and serves as a board member of AdvaMed.